Search

everythinglearnresearchcommunity

for

Search:↓

A user discusses making DIY dutasteride capsules from powder bought from China, using a mix of MCT oil and propylene glycol. Others warn about the risks of incorrect dosing, potential degradation, and the possibility of receiving fake products.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.

Most users did not visit a dermatologist before starting finasteride, opting to purchase it directly or through a primary care physician. Some users shared experiences of side effects and emphasized the potential benefits of medical advice and monitoring.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It highlights the South Korean president's push for public health coverage for hair loss.

Finasteride increased the user's estrogen levels by 51%, causing concerns about gynecomastia and sleep issues. Despite potential side effects, the user prefers continuing finasteride to prevent hair loss, considering it essential for self-esteem.

An 18-year-old experiencing diffuse hair thinning since 8th grade seeks advice. They are concerned about having less hair than their 52-year-old father and are looking for treatment options.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

The conversation discusses potential hair loss treatments, including methylating estrogen, losing body fat, and supplementing with vitamins A, K2, and D. It also mentions reducing exposure to environmental estrogenics, with skepticism about genetic factors being the primary cause of baldness.

Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.